A phase 3 clinical trial called ECLIPSE has shown that 177Lu-PSMA-I&T significantly extends the median radiographic progression-free survival (rPFS) compared to hormone therapy in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) previously treated with an ARPI (but I don't know which arpis were considered...will have to find out).
NOTE: rPFS was the first data to mature and from what I understand, median was 34 weeks, OS median not reached
The trial enrolled over 400 patients globally and included primary and secondary endpoints like rPFS, overall survival, and quality-of-life measures. The investigators also plan to conduct a substudy to assess pharmacokinetic and radiation dosimetry.
Hi Maxone, must say I am delighted to see the word 34 months but it also confuses me.Generally speaking once stage4 castrate resistant person got resistant with abi or enza, if pluvicto is applied median rpfs is 12-15 months, and I see frequent worst stories here.
Is this I&T version. Of LU 177 any different?
This 34 months, as I read it, looks like this is applied after patient got resistant with abi or enza or daro or...or it is applied as a first line on de novo metastatic patients?
34 weeks, but i am rrying to understand if I can find the actual complete data. I think the source is confused itself. You use it after the first line ARSI failed. What they say is that instead of switching to a different ARPI this solution is better. I must investigate more.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
Welcoming New Era of Expanded Use of Radiotherapies
BLUE SKY NEWS - AUGUST 2022
Monoamine oxidase A (MAOA): A promising target for prostate cancer therapy